CCN2 and systemic sclerosis: The inhibition of oncostatin M in SSc patients is now under evaluation in a phase II clinical trial [43,117], while the blockade of CTGF with a monoclonal antibody was shown to ameliorate skin fibrosis in SSc mouse models and to retard the decline in forced vital capacity in patients with idiopathic pulmonary fibrosis [43,117,195].